Tech Company Financing Transactions

Feldan Therapeutics Funding Round

Amgen Ventures, FSIT2 and GC Cell joined a $16.5 million Series B funding round for Feldan Therapeutics. The round was announced by the company on 6/13/2023.

Transaction Overview

Announced On
6/13/2023
Transaction Type
Venture Equity
Amount
$16,500,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4975 Rideau St. 100
Quebec QC, G2E 5H5
Canada
Email Address
Overview
We produce high-quality cytokines and proteins for your scientific needs.
Profile
Feldan Therapeutics LinkedIn Company Profile
Social Media
Feldan Therapeutics Company Twitter Account
Company News
Feldan Therapeutics News
Facebook
Feldan Therapeutics on Facebook
YouTube
Feldan Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Francois-Thomas Michaud
  Francois-Thomas Michaud LinkedIn Profile  Francois-Thomas Michaud Twitter Account  Francois-Thomas Michaud News  Francois-Thomas Michaud on Facebook
VP - Bus. Development
Vincent Ménard
  Vincent Ménard LinkedIn Profile  Vincent Ménard Twitter Account  Vincent Ménard News  Vincent Ménard on Facebook
VP - Bus. Development
Nancy Messier
  Nancy Messier LinkedIn Profile  Nancy Messier Twitter Account  Nancy Messier News  Nancy Messier on Facebook
VP - Marketing
Meriem Benchabane
  Meriem Benchabane LinkedIn Profile  Meriem Benchabane Twitter Account  Meriem Benchabane News  Meriem Benchabane on Facebook
VP - Operations
Pierre-Alain Moisset
  Pierre-Alain Moisset LinkedIn Profile  Pierre-Alain Moisset Twitter Account  Pierre-Alain Moisset News  Pierre-Alain Moisset on Facebook
VP - R & D
David Guay
  David Guay LinkedIn Profile  David Guay Twitter Account  David Guay News  David Guay on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/13/2023: Pollen venture capital transaction
Next: 6/13/2023: Synthesia venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. VC transactions on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary